Data as of Sep 15
| -1.11 / -2.70%|
The 3 analysts offering 12-month price forecasts for Anika Therapeutics Inc have a median target of 60.00, with a high estimate of 61.00 and a low estimate of 51.50. The median estimate represents a +50.26% increase from the last price of 39.93.
The current consensus among 3 polled investment analysts is to Buy stock in Anika Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.